What Are the Ankylosing Spondylitis Treatment Guidelines?

Treatment guidelines for ankylosing spondylitis follow a stepwise approach: start with anti-inflammatory medications and structured exercise, escalate to biologic drugs when those are not enough, and reserve surgery for advanced joint damage. The most widely referenced recommendations come from the American College of Rheumatology (ACR) and the Assessment of Spondyloarthritis International Society (ASAS), both of which were updated in 2019 to reflect the expanding range of biologic and targeted therapies now available. The picture is more layered than a simple drug ladder, though, because the choice of medication depends on which parts of the body are affected, whether the disease shows up on X-rays yet, and whether you also deal with conditions like inflammatory bowel disease or eye inflammation.

How the Disease Is Classified and Why It Matters for Treatment

Ankylosing spondylitis (AS) sits within a broader category called axial spondyloarthritis (axSpA). The older diagnostic standard, the 1984 modified New York criteria, required visible damage to the sacroiliac joints on plain X-rays. That worked for established disease but missed people in the early inflammatory stage before bone changes showed up. The ASAS classification criteria addressed this gap by allowing MRI findings of active sacroiliitis to count, which means the disease can be identified much earlier than before.¹ Patients are now grouped into radiographic axSpA (which is essentially classic AS with X-ray changes) and non-radiographic axSpA (inflammation visible on MRI but no structural damage on X-rays yet).²

This distinction matters for treatment because the 2019 ACR recommendations treat both groups similarly in terms of the medication sequence, but the evidence base behind some drugs is stronger for radiographic disease. If your rheumatologist talks about “axial spondyloarthritis” rather than just ankylosing spondylitis, they are working within this updated framework.

NSAIDs as the Starting Point

Nonsteroidal anti-inflammatory drugs are the first medication recommended for active disease. The ACR/SAA/SPARTAN 2015 guidelines made this a strong recommendation, meaning the evidence was solid enough and the benefit-to-risk balance favorable enough that most patients with active AS should be offered an NSAID before anything else.³ Unlike how NSAIDs are used for garden-variety back pain, where they are taken as needed, in AS they are often prescribed on a continuous or scheduled basis, because the goal is to suppress ongoing inflammation rather than just mask pain flares.

Most people with AS can tell within a couple of weeks whether an NSAID is helping. If one doesn’t work, switching to a different NSAID is reasonable before jumping to biologics, because individual responses vary. But if two or more NSAIDs at adequate doses fail to control symptoms over roughly four weeks, guidelines say it is time to consider escalation.

Why Conventional Disease-Modifying Drugs Have a Limited Role

If you have rheumatoid arthritis, methotrexate is usually the backbone of treatment. In ankylosing spondylitis, it is not. A 16-week open-label trial of subcutaneous methotrexate in patients with active AS and predominantly spinal symptoms found no benefit beyond what you would expect from a placebo effect.⁴ Sulfasalazine is a partial exception: it can help with peripheral joint inflammation, such as swollen knees or ankles, and is sometimes used in patients who cannot take NSAIDs. But there is no evidence that sulfasalazine improves spinal mobility, enthesitis (inflammation where tendons attach to bone), or overall physical function.⁵

This is one of the areas where AS diverges sharply from other inflammatory joint diseases. The spine does not respond to the same conventional immunosuppressants that work well elsewhere, which is why guidelines skip straight from NSAIDs to biologics for axial symptoms.

Biologic Therapy and the Preferred Sequence

When NSAIDs are not enough, the 2019 ACR update recommends a TNF inhibitor (such as adalimumab, etanercept, infliximab, certolizumab pegol, or golimumab) as the first biologic tried. TNF inhibitors are recommended over IL-17 inhibitors like secukinumab or ixekizumab as the initial biologic choice.⁶ This preference is based on the longer track record and larger body of trial data behind TNF inhibitors, not on evidence that they are dramatically superior in head-to-head comparisons. In fact, direct head-to-head trials between TNF inhibitors and IL-17 inhibitors have been scarce, so the positioning is partly a reflection of familiarity and accumulated safety data.⁷

What happens when the first TNF inhibitor does not work depends on the type of failure. If you had absolutely no response to the first TNF inhibitor (a “primary nonresponse”), the guidelines recommend switching to an IL-17 inhibitor rather than trying a second TNF inhibitor, because a completely different mechanism may be more likely to succeed.⁶ If you initially responded but then lost effectiveness over time (a “secondary nonresponse”), switching to another TNF inhibitor or to an IL-17 inhibitor are both reasonable options.

IL-17 Inhibitors

Secukinumab was the first IL-17A inhibitor approved for AS, followed by ixekizumab. Trial data showed that secukinumab’s benefits held up regardless of whether patients had previously taken a TNF inhibitor, and responses were sustained over five years of treatment.⁸ For people who have failed or cannot tolerate TNF inhibitors, IL-17 blockade offers a genuinely different pathway into the inflammatory process. One important caveat: IL-17 inhibitors are generally avoided in patients with coexisting inflammatory bowel disease, because blocking IL-17 can worsen gut inflammation. TNF inhibitors (especially monoclonal antibodies like adalimumab and infliximab, rather than the receptor-fusion protein etanercept) are the better fit in that scenario.

JAK Inhibitors

A newer class, Janus kinase (JAK) inhibitors, has entered the treatment landscape. Two compounds, tofacitinib and upadacitinib, are now approved for axSpA after clinical trials showed efficacy in patients who had not responded adequately to NSAIDs or biologics.⁹ JAK inhibitors are oral pills rather than injections, which some patients find more convenient. They fill an important gap for people who have cycled through TNF inhibitors and IL-17 inhibitors without adequate control.

The Limited Role of Corticosteroids

One of the strong recommendations in the ACR guidelines is against using systemic (oral) glucocorticoids for AS.³ That said, the reality is a bit more nuanced than a blanket ban. A systematic review pooling data from two small randomized trials found that high-dose oral prednisolone (with or without a taper) was about four times more likely than placebo to produce a major improvement in disease activity over short courses. Pulsed intravenous steroids produced dramatic improvements, though these lasted only weeks to months.¹⁰

Where corticosteroids do have a clearer role is as local injections. Injecting a steroid directly into an inflamed sacroiliac joint or a swollen peripheral joint achieved sustained improvement in roughly half to nine out of ten joints at six months. Entheseal injections (at the points where tendons meet bone) also reduced pain and improved imaging measures.¹⁰ So the guideline advice is really about avoiding long-term oral steroids, not about never touching a steroid in any form.

Exercise and Physical Therapy

Physical therapy is another strong recommendation in the guidelines, placed alongside NSAIDs as a frontline treatment. A Cochrane review found moderate-to-low-quality evidence that exercise programs probably slightly improve function and may reduce pain compared to no intervention at all.¹¹ The effects were modest when exercise was compared to “usual care” (which itself often included some level of activity), and researchers were uncertain about whether exercise specifically improves spinal mobility or reduces fatigue.

That sounds underwhelming if you look purely at the trial numbers, but clinicians and patient advocates argue that exercise plays a role that controlled trials do not fully capture: maintaining posture, preventing deconditioning, and supporting long-term functional independence. The challenge is that detailed guidance on what kind of exercise to do, how often, and at what intensity has historically been lacking. A consensus project combining evidence with clinical expertise was developed specifically to provide more practical prescriptions for sustainable exercise in AS, acknowledging that “exercise is beneficial” is not a useful instruction without specifics.¹² If your rheumatologist tells you to exercise without saying more, ask for a referral to a physiotherapist who has experience with inflammatory spinal conditions.

How Extra-Articular Manifestations Change Drug Selection

AS does not stay confined to the spine in many patients. Acute anterior uveitis (a painful eye inflammation), inflammatory bowel disease, and psoriasis all occur at elevated rates in people with axSpA, and their presence substantially influences which biologic gets chosen. Data from a large UK biologics registry showed that a diagnosis of uveitis or IBD was associated with a strong preference for adalimumab over other TNF inhibitors, while both conditions were associated with significantly less use of etanercept.¹³

The reason is that monoclonal antibody TNF inhibitors (adalimumab, infliximab, certolizumab, golimumab) have better evidence for preventing uveitis flares and controlling gut inflammation than etanercept, which is structurally different. If you have AS plus Crohn’s disease, for instance, your rheumatologist is likely to pick a monoclonal antibody TNF inhibitor that can treat both. If you have AS plus psoriasis but no gut involvement, an IL-17 inhibitor becomes a more attractive option, since secukinumab and ixekizumab are also approved for psoriasis. These overlapping indications mean that the “best” biologic is rarely the same for every patient.

Monitoring Disease Activity and the Treat-to-Target Approach

Guidelines increasingly advocate a treat-to-target strategy, where disease activity is measured at regular intervals and treatment is adjusted until a predefined goal (usually remission or low disease activity) is reached. Two main tools are used: the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS).¹⁴ BASDAI relies entirely on patient-reported symptoms, while ASDAS also incorporates a blood marker of inflammation (CRP), giving it a more objective dimension.

In practice, real-world implementation falls short of the ideal. An observational study in daily practice found that among patients with high disease activity, fewer than a quarter had their disease activity re-assessed within three months, and treatment was adjusted within six weeks in only about one in six patients.¹⁵ If you are living with active disease and your treatment has not been revisited in months, that gap may reflect a missed opportunity rather than a deliberate clinical decision. Asking your rheumatologist about your current ASDAS or BASDAI score and what the treatment target is can help close that gap.

Can You Taper Biologics Once Things Are Under Control?

Biologics are expensive and require injections or infusions, so a natural question once you reach remission is whether you can reduce the dose or stop altogether. The evidence here is cautiously encouraging for tapering but discouraging for full discontinuation. A narrative review of randomized controlled trials found that tapering biologic doses was a feasible strategy to maintain remission or low disease activity, with flare rates comparable to those seen in patients kept on the full dose. However, complete withdrawal of biologics led to an increased risk of flares compared to standard dosing.¹⁶

A prospective multicenter trial of stepwise tapering of an etanercept biosimilar supported this pattern: patients who gradually reduced their dose maintained low flare rates over 48 weeks, and even very low maintenance doses kept a considerable number of patients flare-free. But abrupt discontinuation, even in patients who had achieved clinical remission, led to unacceptable flare rates.¹⁷ The practical takeaway: if you and your rheumatologist want to attempt a dose reduction, do it gradually and with regular monitoring. Stopping cold is not recommended.

Screening Before Starting Biologics

Before any TNF inhibitor or IL-17 inhibitor is prescribed, screening for latent tuberculosis is considered essential. TNF inhibitors suppress a part of the immune system that is critical for keeping latent TB contained, and reactivation can be life-threatening. Standard screening includes a tuberculin skin test or interferon-gamma release assay, a chest X-ray, and a history of TB exposure.¹⁸ Screening for hepatitis B and C is also standard before starting immunosuppressive biologics. If latent TB is found, treatment for it is typically completed before or shortly after starting the biologic.

Cardiovascular Risk and the Bigger Treatment Picture

AS is not just a joint disease. Chronic systemic inflammation raises cardiovascular risk, and European guidelines (EULAR) state that the rheumatologist is responsible for monitoring all AS patients for signs of cardiovascular involvement.¹⁹ Some risk-assessment methods have been adapted for AS patients by adding 15 years to their chronological age to account for the additional inflammatory burden.²⁰ Patients with high blood pressure or abnormal cholesterol should start appropriate treatment for those conditions promptly. Smoking cessation, a balanced diet, and maintaining normal blood pressure, cholesterol, and blood sugar levels are all recommended as part of a comprehensive AS management plan, not merely as general health advice.

Pregnancy and Ankylosing Spondylitis

Women with axSpA face some additional considerations during pregnancy. A systematic review and meta-analysis found a statistically significant increase in cesarean sections in women with axSpA compared to the general population, with elective cesareans roughly twice as common. There were trends toward higher rates of pre-eclampsia, low birth weight, and NICU admissions, though most of these did not reach statistical significance.²¹ Disease management during pregnancy is complicated by the fact that many medications used for AS are not safe during pregnancy. Certolizumab pegol is the TNF inhibitor with the most favorable safety data during pregnancy, because of its unique structure that limits placental transfer, and is often the preferred biologic if treatment is needed during pregnancy.

Surgery for Advanced Disease

The ACR guidelines include a strong recommendation for hip arthroplasty (hip replacement) in patients with advanced hip arthritis from AS.³ In patients who also need a spinal osteotomy (a procedure to correct a fixed forward-bent posture), the sequencing of surgeries matters. A small case series found that performing the spinal correction before the hip replacement generally produced better outcomes, unless the spinal deformity was so severe that the procedure was technically not possible.²² These are major surgeries, and the decision to proceed typically comes only after medical therapy has been optimized and the structural damage is limiting daily life in ways that drugs cannot fix.

Pediatric Spondyloarthritis and Gaps in Evidence

Children can develop a form of spondyloarthritis classified as enthesitis-related arthritis (ERA) under the juvenile idiopathic arthritis framework. Pediatric treatment guidelines recommend biologic drugs as part of early treatment for ERA, but there is a disconnect: several therapies approved for adult peripheral SpA or non-radiographic axSpA, including certolizumab pegol, ixekizumab, and secukinumab, have not been studied or labeled for use in children with ERA.²³ Pediatric rheumatologists often end up borrowing from the adult evidence base while navigating the reality that the drugs they want to use lack pediatric approval. This remains one of the most significant unaddressed gaps in spondyloarthritis treatment.

Digital Tools and Self-Management

An emerging area in AS management is the use of digital health applications, particularly for pain management and behavioral strategies. A randomized controlled trial tested a digital behavioral therapy app based on acceptance and commitment therapy in patients with axSpA and persistent pain. Patients using the app showed greater improvements in pain-related interference with daily life and in emotional distress compared to standard care alone.²⁴ These tools are not replacements for medication or physical therapy, but they address something that the traditional treatment ladder does not: the psychological burden of living with chronic inflammatory pain. For a disease where roughly a third to two-fifths of patients remain in high disease activity even after treatment adjustments, anything that helps people function better day to day fills a real gap.